international patient survey of mps i disease management l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
International Patient Survey of MPS I Disease Management PowerPoint Presentation
Download Presentation
International Patient Survey of MPS I Disease Management

Loading in 2 Seconds...

play fullscreen
1 / 13

International Patient Survey of MPS I Disease Management - PowerPoint PPT Presentation


  • 342 Views
  • Uploaded on

International Patient Survey of MPS I Disease Management A collaboration of Genzyme and national MPS societies Presented to the 10 th International Symposium of Mucopolysaccharide and Related Diseases, Vancouver, June 2008 ©Genzyme Corporation 2008 Objectives

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'International Patient Survey of MPS I Disease Management' - Leo


Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
international patient survey of mps i disease management

International Patient Survey ofMPS I Disease Management

A collaboration of Genzyme and national MPS societies

Presented to the 10th International Symposium

of Mucopolysaccharide and Related Diseases,

Vancouver, June 2008

©Genzyme Corporation 2008

objectives
Objectives
  • Learn from individuals with MPS I (and parents/guardians) about current health, both physical and emotional
  • Examine their experience of transplantation and enzyme replacement therapy with laronidase (Aldurazyme), and how well these therapies live up to expectations in managing symptoms and improving quality of life
  • Obtain input on support services provided by Genzyme and national MPS societies in order to plan programs that encourage optimal treatment across the spectrum of MPS I
methodology
Methodology
  • Survey design
    • 8-page questionnaire designed by Genzyme in collaboration with national MPS societies; translated into local languages
  • Survey distributed & collected by national MPS societies
    • Mail: Japan, Australia, Canada, US, Netherlands, Germany
    • Society meeting: Poland, Brazil
    • Telephone: UK
  • Survey period
    • September-October 2006 (US)
    • June-November 2007 (all other participating countries)
  • Survey participation
    • 45% response rate
    • 238 completed questionnaires: Japan (9), Australia (9), Canada (17), US (61), UK (83), Netherlands (10), Germany (14), Poland (14), Brazil (21)
slide4
Self-assessment of most MPS I patients’ health is positive on overall physical and emotional measures

Overall Health Assessment

Emotional Health

Physical Health

Higher favorable scores for Hurler (45% Ex/VG), <1 year old at transplant (80%)

Higher unfavorable scores for Hurler-Scheie (29% Fair/Poor), Scheie (27%)

Higher unfavorable scores for Hurler-Scheie (20% Fair/Poor)

Q4. On most days, how would you rate your . . . Physical health? (N=237). . . Emotional health? (N=235)

slide5
84% of recipients rate transplantation performance highly favorably (8,9,10 ratings), including majority rating “10”

1=Extremely Poor

10=Extremely Well

No “1,2,3” ratings received

Mean Score: 8.95

Q14. Based on your experience to date, how would you rate the overall performance of transplant therapy as a treatment for MPS I? (N=103)

slide6
Transplantation patients report “a lot” or “some” improvement on many parameters (including mental development); less on musculoskeletal

Q15. How much improvement, if any, do you believe transplant therapy has had on your health and symptoms in each of these areas? (N=103)

slide7
The earlier that patients receive transplant, the more likely they are to experience improvement on several health parameters

Age at

transplant

Musculoskeletal

Respir

Cranio

Vision

Abdomin

Sleep

Cardiac

Mental

QoL

Perceived Improvement

Q25. How much improvement, if any, do you believe transplant therapy has had on your health and symptoms in each of these areas? (N=10 <1 year old at transplant [caution, small sample size]; N=93 age 1+ at transplant)

a 63 majority rate enzyme replacement therapy performance highly favorably 8 9 10 ratings
A 63% majority rate Enzyme Replacement Therapy performance highly favorably (8,9,10 ratings)

1=Extremely Poor

10=Extremely Well

Mean Score: 8.14

Q24. Based on your experience to date, how would you rate the overall performance of ERT as a treatment for MPS I? (N=135)

slide9
Widespread reports of improvements from ERT on quality of life and physical symptoms, including musculoskeletal
  • The most improvements across parameters reported:
  • Hurler and Hurler-Scheie
  • Age <6
  • Currently on ERT 3+ yrs
  • The least improvements across parameters reported:
  • Scheie
  • Age 6-17
  • Currently on ERT <3 yrs

Q25. How much improvement, if any, do you believe ERT has had on your health and symptoms in each

of these areas? (N=133)

slide10

The longer that patients receive ERT, the better their reported outcomes on musculoskeletal, respiratory, abdominal, cardiac and quality of life

Time on

ERT

Musculoskeletal

Respir

Cranio

Vision

Abdomin

Sleep

Cardiac

Mental

QoL

Perceived Improvement

Q25. How much improvement, if any, do you believe ERT has had on your health and symptoms in each of these areas? (N=47 currently on ERT <3 yr; N=63 currently on ERT 3+ yr)

slide11
ERT adherence rate is high; however, 2 in 10 patients report missing four or more consecutive infusions

Biggest gaps in adherence reported among Hurler-Scheie (25%), Poland (57%), Canada (33%), Brazil (30%)

Highest adherence rates among patients on home infusion (100%), Scheie (93%), US (97%), Australia (100%), Japan (100%)

  • The main reasons reported for missing infusions are:
  • health related, i.e., hospitalization, surgery, feeling too sick, pregnancy
  • scheduling problems, i.e., too busy, traveling, moving, vacationing
  • Drug not available and/or financial/insurance issues especially in Poland, Brazil

Q20. Have/had you ever missed 4 or more consecutive infusions? (N=134) Q21. Which of the following items, if any,

describe the main reasons you missed or stopped ERT? (N=134)

in addition to those already receiving home infusion many other respondents express high interest
In addition to those already receiving home infusion, many other respondents express high interest

Home infusion experience reported in US (40%), Netherlands (56%), Germany and Canada

Greatest additional interest in Canada (88%, 7 out of 8 patients extremely interested) and UK 62%

Q32. How interested would you be in each of the following types of ERT administration and infusion methods? Home infusion:A nurse or clinician comes to your home to prepare the solution and administer the infusion. (N=89 currently on ERT)

conclusions
Conclusions
  • MPS I patients receiving therapy give overall positive reports on physical and emotional health and high satisfaction rates for both transplantation and ERT.
  • Among transplanted patients, 60% reported complications and 26% repeat procedures; however, fully 84% rated transplantation performance highly favorably (mean score 8.95 on a 1-10 scale) and 75% reported some/a lot of improvement on mental development.
    • Overall, the earlier the transplant, the greater the satisfaction. Lowest rates of satisfaction were with cardiac, visual, and musculoskeletal symptoms.
  • Among patients who received ERT, 63% rated performance highly favorably (mean score 8.14), with highest ratings for quality of life, gastrointestinal, sleep, and musculoskeletal symptoms and the lowest ratings for mental development, cardiac, craniofacial, and visual symptoms.
    • The longer the patients were on ERT, the greater their satisfaction with treatment.